SCOTTS INTERNATIONAL

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029

Market Report | 2025-01-28 | 578 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User $4950.00
- Multi User $6650.00
- Corporate License $8150.00
- Enterprise Site License $10000.00

Report description:

The point of care diagnostics market is estimated to reach USD 22.63 billion in 2029 from the forecasted value of USD 15.05 billion in 2024 at a CAGR of 8.5%. One of the primary reasons that will fuel POC testing is the favourable government initiatives and funding. Globally, governments consider these technologies essential in improving the accessibility of health care, bringing down costs, and enhancing outcomes for patients. Many governments also provide financial support in addition to the provision of grants with regulatory incentives to focus on the development and adoption of POC testing solutions. In developing countries with a lack of proper health care facilities, the governments encourage using POC devices abundantly, decentralizing tests for more underserved populations. Such supportive measures accelerate the adoption of POC diagnostics and thus are opening new market opportunities for diagnostic companies.
"Infectious disease testing products segment is expected to have the fastest growth rate in the point of care diagnostics market, by product, during the forecast period."
The point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products, based on product. Infectious disease testing products are expected to witness the fastest growth in the point of care diagnostics market, mainly driven by the high prevalence of infectious diseases worldwide. The increased demand for fast, accurate, and decentralized healthcare diagnostic solutions for community clinics and rural health centers has been driving the demand in this segment.

Improved technologies that include faster molecular diagnostics and enhanced immunoassay platforms enhance the speed and efficiency of accuracy in POC testing. Moreover, with an increase in public health initiatives and growing awareness of the POC solutions for infectious diseases, adoption of these products is increasing significantly.
"Blood samples segment accounted for the largest market share in the point of care diagnostics market, by sample, during the forecast period."
Based on sample, the point of care diagnostics market is bifurcated into blood samples, urine samples, nasal and oropharyngeal swabs, and other samples. The largest market share is held by blood samples in the point of care diagnostics market. Their critical role lies in detecting the broad spectrum of conditions such as diabetes, cardiovascular diseases, infectious diseases, and metabolic disorders. Blood-based tests are considered accurate, reliable, and offer have high turnaround times for results. Because of this reason, these are the most opted sample type for both clinical and near-patient environments. Also, efficiency in blood-based POC devices has been enhanced by the technological advancements which result in accurate results with minimum sample volumes. Additionally, chronic and infectious diseases continue to be on rise, which is accompanied by a high demand for rapid and convenient diagnostic solutions requiring blood-based tests, which has helped maintain the dominance of blood samples in this market.
"Asia Pacific: The fastest-growing market for point of care diagnostics"
The worldwide market for point of care diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The Asia Pacific region is experiencing significant growth in the point of care diagnostics market due to several factors. Government efforts to promote early disease detection, prevention, and regular health check-ups is a key driver, with a number of initiatives that encourage widespread health screening and timely intervention. These efforts, coupled with the rising healthcare expenditure across the region, have increased the accessibility and demand for diagnostic solutions. The increasing numbers of chronic conditions, such as diabetes in countries such as India and China have also increased the demand for fast and accurate diagnostic equipment. Improving public health results by early diagnosis and management is enabling more healthcare systems to become involved in adopting POC diagnostics in this region.

The break-up of the profile of primary participants in the point of care diagnostics market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Other- 4%

The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMerieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), Boditech Med Inc. (South Korea), Grifols, S.A. (Spain), LifeScan IP Holdings, LLC (US), PTS Diagnostics (US), Eurolyser Diagnostica GmbH (Austria), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), BTNX Inc. (Canada), Ascensia Diabetes Care Holdings AG (Switzerland), Fluxergy (US), Precision Biosensor, Inc. (South Korea), ACON Laboratories, Inc. (US), Menarini Diagnostics s.r.l (Italy), OraSure Technologies, Inc. (US), and Mankind Pharma (India) .
Research Coverage:
This research report categorizes the point of care diagnostics market by product (glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products), by mode of purchase (OTC testing products and prescription-based testing products), by technology (immunoassays, molecular diagnostics, and biochemistry), by sample (blood samples, urine samples, nasal & oropharyngeal swabs, and other samples), by end user (clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the point of care diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies,

acquisitions, and agreements. New product & service launches, and recent developments associated with the point of care diagnostics market. Competitive analysis of upcoming startups in the point of care diagnostics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall point of care diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing incidence of infectious disease, increasing prevalence of chronic diseases, favourable government initiatives for point of care testing, and rising number of waived tests), opportunities (Increasing growth potential in emerging markets, rising inclination toward decentralized healthcare system, booming healthcare spending worldwide), restraints (Pricing pressure on manufacturers and stringent regulatory approval process for product commercialization), and challenges (Inadequate standardization with centralized lab methods and premium pricing of novel platforms) influencing the growth of the point of care diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the point of care diagnostics market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the point of care diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the point of care diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), QuidelOrtho Corporation (US), and Danaher (US).

Table of Contents:

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029

Market Report | 2025-01-28 | 578 pages | MarketsandMarkets

To place an Order with Scotts International:
- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	$4950.00
	Multi User	$6650.00
	Corporate License	$8150.00
	Enterprise Site License	$10000.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.
** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	

Zip Code*		Country*	
		Date	2025-05-17
		Signature	